SGLT-3 activators are a class of chemical compounds that specifically enhance the activity of the sodium-glucose cotransporter-3 (SGLT-3) protein. Unlike its counterparts SGLT-1 and SGLT-2, which are primarily involved in glucose transport in the kidney and intestines, SGLT-3 does not seem to transport glucose but instead functions as a glucose sensor. The activation of SGLT-3 is unique in that it leads to the depolarization of cell membranes without the translocation of glucose across the membrane. This is believed to be due to the transporter's ability to conduct ions in response to glucose levels. The precise mechanisms by which SGLT-3 activators enhance the protein's activity involve the binding of these compounds to the transporter, leading to conformational changes that increase its ion conductance properties. This activity is thought to play a role in the regulation of glucose homeostasis and could have implications in sensing and signaling processes in tissues where SGLT-3 is expressed, such as the enteric nervous system and certain regions of the brain.
The chemical structure of SGLT-3 activators can vary, but they typically share an affinity for the SGLT-3 binding site and possess functional groups capable of interacting with the protein's glucose recognition domains. This interaction prompts alterations in the transporter's structure, enhancing its ability to conduct sodium ions. The activation of SGLT-3 by these compounds results in a subsequent depolarization of the cellular membrane, which can trigger a cascade of intracellular signaling events that are important for maintaining the cellular response to extracellular glucose levels. These signaling pathways may involve changes in the activity of various ion channels or the modulation of downstream signaling molecules, ultimately influencing cellular functions that are responsive to changes in glucose concentrations. It is important to note that while these activators specifically target SGLT-3, their selectivity and the full scope of their effects on cellular metabolism and signaling remain areas of active investigation within the field of molecular pharmacology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phloridzin dihydrate | 7061-54-3 | sc-215708 sc-215708A | 250 mg 1 g | $49.00 $119.00 | ||
Phlorizin is a competitive inhibitor of SGLT-1 and SGLT-2; however, it enhances SGLT-3 activity by binding to SGLT-2, thereby reducing its glucose reabsorption ability in the kidney leading to a compensatory increase in SGLT-3 activity. | ||||||
D(+)Glucose, Anhydrous | 50-99-7 | sc-211203 sc-211203B sc-211203A | 250 g 5 kg 1 kg | $38.00 $198.00 $65.00 | 5 | |
Glucose is a direct substrate of SGLT-3 and its presence increases the functional transport activity of SGLT-3, leading to enhanced glucose uptake through the transporter. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin can increase the activity of SGLT-3 by promoting its translocation to the plasma membrane through PI3K/Akt signaling pathways, which are known to mediate glucose transporter trafficking. | ||||||
Dapagliflozin | 461432-26-8 | sc-364481 sc-364481A sc-364481B | 5 mg 50 mg 1 g | $117.00 $428.00 $1051.00 | 6 | |
Dapagliflozin is a selective SGLT-2 inhibitor but can indirectly enhance SGLT-3 activity by increasing circulating glucose levels due to reduced renal glucose reabsorption, potentially increasing SGLT-3 mediated uptake. | ||||||
Empagliflozin | 864070-44-0 | sc-482194 sc-482194A sc-482194B sc-482194C | 1 g 5 g 10 g 100 g | $165.00 $322.00 $407.00 $1221.00 | 5 | |
Similar to Dapagliflozin, Empagliflozin is an SGLT-2 inhibitor that may indirectly increase SGLT-3 activity by elevating blood glucose levels, which in turn could enhance SGLT-3-mediated glucose uptake. | ||||||
Canagliflozin | 842133-18-0 | sc-364454 sc-364454A | 5 mg 50 mg | $312.00 $416.00 | 2 | |
Canagliflozin is another SGLT-2 inhibitor that can indirectly increase SGLT-3 activity by causing an elevation in systemic glucose levels due to reduced glucose reabsorption in kidneys, possibly increasing uptake by SGLT-3. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels, which can enhance SGLT-3 activity by promoting its translocation to the cell membrane. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
Glyburide, a sulfonylurea, can enhance SGLT-3 activity indirectly by stimulating insulin release, which then promotes the translocation of SGLT-3 transporters to the plasma membrane. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, a PPAR-gamma agonist, can enhance SGLT-3 activity indirectly via its insulin-sensitizing effects that increase glucose uptake mechanisms, including the activity of SGLT-3 transporters. | ||||||